

This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

Notices

- Appriss has been awarded the contract to provide PDMP services
- The PDMP received the notice of award for the Bureau of Justice Assistance (BJA) grant and are revising our budget based on the funding received
- Analysis of Awareness and Feedback Questionnaire published (110 pharmacists participated)

Registration

Decreases in registration could be the result of license clean up done after renewal was complete

Portal

- Number of licensed Pharmacists: 1,040 (decrease of 147 licenses)
- Number of PDMP Pharmacist registrations: 718 (decrease of 59 registrations)
- Number of Pharmacists dispensing: 638 (decrease of 34 pharmacists)
- Compliance rate (PDMP registration and dispensing): 113%

AWARxE (PDMP)

- Number registered with the PDMP: 763 (decrease of 46 registrations)
- Compliance rate (PDMP registrations and dispensing): 120%

Delinquent Reporters

- Letters sent to 94 licensees on January 26, 2021
 - 16 dispensers responded to obtain list of delinquent dates
 - 8 providers responded to clarify they are not dispensing

Recommendations

- Encourage the use of authorized delegates.
- Encourage licensees to verify their user roles and specialties in AWARxE to improve the accuracy of reporting.

Recommendations to Prescribing Boards

- Encourage increased reviewing, including the use of authorized delegates.
- Issue periodic reminders to licensees on mandatory reviewing and reporting.
- Provide guidance to licensees on prescribing practices related to the use of dangerous combinations.
- Encourage licensees to verify their user roles and specialties in AWARxE to improve the accuracy of reporting.
- Providers should be notified they are not able to prescribe federally scheduled II and III controlled substances until their registration in AWARxE has been approved.
- Set daily MME in regulation.
- Develop a plan for following up with delinquent reporters.
- Improve communication to licensees, post-licensure, to give better instructions on how to comply with PDMP statutes and regulations.

Alaska Prescription Drug Monitoring Program
Summary Prepared for the Board of Pharmacy
February 2021



MME Use
Q3/Q4 2020

The CDC recommends that primary care clinicians should reassess evidence of the benefits and risks to the individual when increasing dosage to greater or equal to 50 MME/day and avoid increasing to greater or equal to 90 MME/day when possible due to an increased risk of complications. The CDC also recommends avoiding concurrent benzodiazepine and opioid prescriptions, given the high risk of adverse drug-drug interactions, specifically respiratory depression and death.

CDC checklist for prescribing opioids -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDC_06.2018.pdf

CDC guidelines for prescribing opioids for chronic pain -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDCPain_2018.10.pdf

Provider Type	# Providers Prescribing at Least Once	# Providers Who Reviewed 0 Patients	# Providers Prescribing >90MME	# Providers Prescribing >120MME	Dangerous Combo	
					Benzo Opioid	Benzo Opioid Carisoprodol
DEN	321	59% (188)	7% (22)	2% (7)	27% (88)	0
MED	1235	31% (384)	21% (265)	12% (151)	35% (428)	2% (21)
NUR	528	20% (109)	11% (60)	7% (35)	25% (130)	2% (8)
OPT	3	100% (3)	0	0	0	0
PA	359	19% (67)	18% (66)	14% (51)	29% (103)	1% (5)
VET	187	71% (133)	2% (3)	1% (2)	4% (7)	0